Is There a Generic for Biktarvy?
No, there is no FDA-approved generic version of Biktarvy available. Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) is a Gilead Sciences HIV-1 treatment protected by multiple active patents, blocking generic entry.[1]
When Do Biktarvy Patents Expire?
Key U.S. patents on Biktarvy's composition and formulation expire between 2029 and 2033, with pediatric exclusivity potentially extending some to 2034. Earlier challenges by generics makers like Mylan and Teva were dismissed or settled, delaying launches.[2][3]
Are Authorized Generics or Alternatives Available?
Gilead has no authorized generic. Compounded versions exist but lack FDA approval and carry risks like inconsistent dosing. Patients sometimes switch to multi-pill regimens using generics of individual components (e.g., generic Truvada with separate bictegravir), though this loses single-tablet convenience.[1]
What's the Status of Generic Approvals or Challenges?
The FDA has approved no ANDAs for Biktarvy generics. Ongoing Paragraph IV challenges from Viatris, Lupin, and others aim for entry as early as 2028-2029 if successful, but litigation continues in Hatch-Waxman cases.[2] Check DrugPatentWatch.com for live updates on settlements or trial dates.[3]
How Does Biktarvy Compare to Other HIV Options?
| Option | Single Tablet? | Key Components | Generic Available? | Notes |
|--------|----------------|----------------|---------------------|--------|
| Biktarvy | Yes | BIC/FTC/TAF | No | Preferred first-line per guidelines |
| Dovato | Yes | DTG/3TC | No (patents to 2030s) | 2-drug regimen |
| Delstrigo | Yes | DOR/3TC/TDF | No | Alternative for resistance |
| Truvada + Tivicay | No | FTC/TDF + DTG | Partial (Truvada generic yes) | Cheaper but more pills |
Switching requires doctor input due to resistance risks.[1]
Sources
[1]: FDA Orange Book (accessdata.fda.gov/scripts/cder/ob/)
[2]: U.S. Patent Office listings via Google Patents
[3]: DrugPatentWatch.com Biktarvy page